OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx is supported by a business model that embeds marketing directly into the point-of-care workflow, reaching more than 2M HCPs and 240M patients through roughly 300 EHR and eRx platforms, which creates a differentiated, high-margin channel for pharma brands. Even after revenue guidance was reset to $95M-$100M from $118M-$124M, EBITDA guidance of $21M-$25M held, with 2Q26 EBITDA margin expanding to 24.1% and gross margin reaching 76.5%, showing strong operating leverage, disciplined cost control, and a shift toward higher-margin DAAP and programmatic revenue. The outlook is further strengthened by a repaired balance sheet after the May 2026 refinance to a $35M facility at about 6.5%, net cash of $5.1M, and a credible second growth engine in DeepIntent, while any recovery in the lost 10%-of-2025-sales customer would be incremental upside.

OptimizeRx is facing a fundamentally fragile revenue base because 2026 guidance of $95M–$100M depends on a steep 4Q26 ramp and assumes zero contribution from a lapsed customer, even as net revenue retention fell below 100% in 2Q26 and a top 3 client disruption already forced two revenue cuts. The company’s business remains highly concentrated and exposed to life-sciences budget pressure, MFN and IRA policy risk, and partner dependency, with three customers above 10% of 2025 revenue and 54% of TTM revenue coming from the top 20 pharma manufacturers. Although margins and net cash have improved, the transition away from managed services to higher-margin software is still creating execution risk and near-term revenue volatility, making the recovery appear uncertain rather than durable.